Prelude Therapeutics Ownership | Who Owns Prelude Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Prelude Therapeutics Ownership Summary


Prelude Therapeutics is owned by 35.74% institutional investors, 9.93% insiders, and 54.32% retail investors. Orbimed advisors is the largest institutional shareholder, holding 14.36% of PRLD shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 1.31% of its assets in Prelude Therapeutics shares.

PRLD Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockPrelude Therapeutics35.74%9.93%54.32%
SectorHealthcare Stocks 42.54%10.83%46.63%
IndustryBiotech Stocks 45.22%10.75%44.04%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Orbimed advisors10.91M14.36%$15.71M
Baker bros. advisors lp10.12M13.32%$14.58M
Boxer capital2.57M3.39%$9.79M
Blackrock1.07M1.41%$4.07M
Vanguard group992.85K1.31%$1.43M
Price t rowe associates inc /md/876.34K1.15%$1.26M
Renaissance544.00K0.72%$783.36K
Acadian asset management540.57K0.71%$777.00K
Millennium management462.56K0.61%$589.76K
Morgan stanley284.20K0.37%$409.25K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Boxer capital2.57M0.52%$9.79M
Orbimed advisors10.91M0.37%$15.71M
Baker bros. advisors lp10.12M0.11%$14.58M
Shay capital100.00K0.01%$144.00K
Gsa capital partners llp75.16K0.01%$108.00K
Bridgeway capital management53.50K0.00%$77.04K
Acadian asset management540.57K0.00%$777.00K
Xtx topco15.58K0.00%$22.43K
Renaissance544.00K0.00%$783.36K
Two sigma advisers, lp222.70K0.00%$320.69K

Top Buyers

HolderShares% AssetsChange
Millennium management462.56K0.00%302.03K
Susquehanna group, llp72.80K-72.80K
Vanguard group992.85K-60.28K
Prudential financial25.84K-25.84K
Shay capital100.00K0.01%25.00K

Top Sellers

HolderShares% AssetsChange
Deerfield management company, l.p. (series c)---3.77M
Exoduspoint capital management, lp---921.62K
Avidity partners management lp---890.00K
Massachusetts financial services co /ma/---494.50K
Sio capital management---320.39K

New Positions

HolderShares% AssetsChangeValue
Susquehanna group, llp72.80K-72.80K$92.82K
Prudential financial25.84K-25.84K$37.21K
Hrt financial lp16.90K0.00%16.90K$24.00K
Aqr capital management12.49K-12.49K$15.93K
Optiver b.v.20.00-20.00$29.00

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-1.00
Capital performance advisors llp-8.00
True wealth design-13.00
Highmark wealth management-50.00
Russell investments group-76.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202544-2.22%27,161,9481.82%352.90%15-11.76%18-14.29%
Jun 30, 202549-14.04%27,188,001-4.17%352.57%19-9.52%23-4.17%
Mar 31, 202557-6.56%30,474,260-5.26%402.23%22-35.29%24118.18%
Dec 31, 202422-69.01%4,265,950-88.07%50.25%12-67.57%4-78.95%
Sep 30, 20247114.52%35,754,6825.42%472.35%3748.00%19-9.52%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard US Total Market Shares ETF720.43K1.31%-
Vanguard Total Stock Mkt Idx Inv705.02K1.25%-15.41K
T. Rowe Price Health Sciences653.96K1.16%-7.26K
Biotech Growth Ord346.50K0.61%-
MFS New Discovery I327.70K0.60%-
T. Rowe Price Small-Cap Value168.61K0.31%-90.00
Fidelity Small Cap Index144.77K0.26%-
Vanguard Institutional Extnd Mkt Idx Tr142.55K0.25%-64.96K
MFS VIT New Discovery Init104.99K0.19%-
State St Russell Sm/Mid Cp® Indx NL Cl C104.70K0.19%-

Recent Insider Transactions


DateNameRoleActivityValue
Mar 25, 2025Combs Andrew Chief Chemistry OfficerBuy$69.25K
Mar 25, 2025Vaddi Krishna CEOBuy$467.44K
Mar 20, 2025Vaddi Krishna CEOBuy$3.95K
Mar 21, 2025Vaddi Krishna CEOBuy$10.96K
Mar 17, 2025Vaddi Krishna CEOBuy$6.83K

Insider Transactions Trends


DateBuySell
2025 Q4--
2025 Q3--
2025 Q2--
2025 Q18-
2024 Q47-

PRLD Ownership FAQ


Who Owns Prelude Therapeutics?

Prelude Therapeutics shareholders are primarily institutional investors at 35.74%, followed by 9.93% insiders and 54.33% retail investors. The average institutional ownership in Prelude Therapeutics's industry, Biotech Stocks , is 45.22%, which Prelude Therapeutics falls below.

Who owns the most shares of Prelude Therapeutics?

Prelude Therapeutics’s largest shareholders are Orbimed advisors (10.91M shares, 14.36%), Baker bros. advisors lp (10.12M shares, 13.32%), and Boxer capital (2.57M shares, 3.39%). Together, they hold 31.07% of Prelude Therapeutics’s total shares outstanding.

Does Blackrock own Prelude Therapeutics?

Yes, BlackRock owns 1.41% of Prelude Therapeutics, totaling 1.07M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 4.07M$. In the last quarter, BlackRock decreased its holdings by -28.558K shares, a -2.60% change.

Who is Prelude Therapeutics’s biggest shareholder by percentage of total assets invested?

Boxer capital is Prelude Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.52% of its assets in 2.57M Prelude Therapeutics shares, valued at 9.79M$.

Who is the top mutual fund holder of Prelude Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Prelude Therapeutics shares, with 1.31% of its total shares outstanding invested in 720.43K Prelude Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools